New Lung Cancer Treatment Approved in Australia, Singapore

Patients battling one of the most aggressive forms of lung cancer now have a promising new weapon in their fight. Australia and Singapore have approved a breakthrough combination therapy that significantly extends survival for people with extensive-stage small cell lung cancer.

The new treatment pairs ZEPZELCA with atezolizumab as a maintenance therapy after initial chemotherapy. Small cell lung cancer affects up to 15% of lung cancer patients and spreads rapidly, often reaching other organs before diagnosis.

The numbers tell a hopeful story. In clinical trials involving 483 patients across 13 countries, people receiving the combination therapy lived a median of 13.2 months compared to 10.6 months with single-drug treatment. The time before their cancer progressed more than doubled, jumping from 2.1 months to 5.4 months.

Professor Nick Pavlakis from Royal North Shore Hospital in Sydney called the approval an important step forward. He noted that most small cell lung cancer patients face limited treatment options and high relapse rates, making new therapies critically needed.

The approval matters deeply for the region. Australia sees roughly 15,000 lung cancer diagnoses annually, while Singapore recorded nearly 10,000 new cases between 2019 and 2023. Small cell lung cancer carries a five-year survival rate below 7%, making every improvement significant.

ZEPZELCA works by damaging cancer cell DNA to slow or stop tumor growth. The drug comes from marine-based compounds, developed by European company PharmaMar after 40 years of ocean research. Specialised Therapeutics will distribute the treatment across Australia, New Zealand, Singapore, Malaysia, Thailand and Vietnam.

The approval came through Project Orbis, an international collaboration that speeds access to cancer treatments. This marks the eighth time Specialised Therapeutics has successfully used this pathway since 2021.

Why This Inspires

This breakthrough reminds us that progress against even the most challenging cancers continues. While outcomes remain difficult, each advancement gives patients precious additional time with loved ones. The collaboration between researchers across continents shows what's possible when scientists unite around a common goal.

Carlo Montagner, CEO of Specialised Therapeutics, emphasized the human impact. The treatment gives eligible patients and their doctors more options to find what works best, improving quality of life and creating more moments with family.

Thousands of families facing devastating diagnoses now have renewed reason for hope.